GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theriva Biologics Inc (FRA:SFY) » Definitions » Research & Development

Theriva Biologics (FRA:SFY) Research & Development : €13.68 Mil (TTM As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Theriva Biologics Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Theriva Biologics's Research & Development for the three months ended in Mar. 2024 was €3.18 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €13.68 Mil.


Theriva Biologics Research & Development Historical Data

The historical data trend for Theriva Biologics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theriva Biologics Research & Development Chart

Theriva Biologics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.98 4.22 6.90 11.07 13.12

Theriva Biologics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.78 2.89 3.75 3.85 3.18

Theriva Biologics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €13.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theriva Biologics  (FRA:SFY) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Theriva Biologics Research & Development Related Terms

Thank you for viewing the detailed overview of Theriva Biologics's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Theriva Biologics (FRA:SFY) Business Description

Traded in Other Exchanges
Address
9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11, leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Theriva Biologics (FRA:SFY) Headlines

From GuruFocus

SOFI WEALTH, LLC Goes on Buying Spree in 2nd Quarter

By GuruFocus Research GuruFocus Editor 07-25-2022